Ad-haccines caused the pediatric hep crisis?
The tip of a titanic iceberg: http://bit.ly/research2000
Hepatitis in children
Human adenovirus type 41 has been identified in 72% (not all) hepatitis cases in children. [1] Adenovirus causes hepatitis in immunocompromised children. [2] They might contribute to liver injury in healthy children. [3]
Yet, considering the small number of children and the widespread prevalence of adenovirus type 41, it can’t be the cause. Other factors must necessarily be involved.
“All patients received negative test results for hepatitis viruses A, B, and C, and several other causes of pediatric hepatitis and infections were ruled out including autoimmune hepatitis, Wilson disease, bacteremia, urinary tract infections, and SARS-CoV-2 infection. None of the children had documented history of previous SARS-CoV-2 infection. Adenovirus was detected in whole blood specimens from all patients by real-time PCR testing. Liver biopsies from six patients demonstrated various degrees of hepatitis with no viral inclusions observed, no immunohistochemical evidence of adenovirus, or no viral particles identified by electron microscopy. Plasma specimens from these two patients were negative for adenovirus by real-time PCR testing upon arrival at the receiving medical facility, but both patients received positive test results when retested by the same real-time PCR test using a whole blood specimen.”: [4]
Pathogen testing result, no. positive/total no.
Adenovirus (whole blood)
9/9
EBV¶
6/9
Enterovirus/Rhinovirus
4/8
Metapneumovirus
1/8
Respiratory syncytial virus
1/8
Human coronavirus OC43
1/8
SARS-CoV-2**
0/9
Hepatitis A/B/C
0/9
They key factor wasn’t present a year ago, it must be recent (unless the hepatitis epidemic was being undetected before that).
Other childhood vaccine recently introduced (new flu shots [5]) or contaminated with adenovirus or other element before the epidemic detection? rGO?
Covid-19 Induced Hepatitis (CIH) has been detected in adults[6] and children. [7] Considering haccines flood the body with toxic COVID spike protein, it’s no surprise they cause the same effect. There are cases of autoimmune hepatitis after COVID vaccination. [8]
COVID vaccines can’t be discarded as a co-factor for children over 5, but also for under-5, if reports of un-vaccination were inaccurate, possibly because parents/doctors were afraid to recognize the children were vaccinated in spite of un-approval below that age (USA, UK, EU).
“There may be a cofactor causing a normal adenovirus to produce a more severe clinical presentation in young children, such as increased susceptibility due to reduced exposure during the pandemic, prior SARS-CoV-2 or other infection, or a yet undiscovered coinfection or toxin. Alternatively, there may have been emergence of a novel adenovirus strain with altered characteristics.” [9]
Suspiciously, studies don’t provide the vaccination records.
· Johnson & Johnson uses a modified type 26 adenovirus (Ad26).
· Cansino uses Ad5
· Sputnik uses Ad26 and Ad5 for its second dose
· AstraZeneca uses a chimpanzee adenovirus.
Could Advaxxes in adults have caused a hybrid adCOVID monster which is affecting children?:
Adenovirus Vax replication problem
Also, “Adenoviruses express two types of genes: early genes and late genes. Early genes (E1A, E1B, E2, E3, and E4) are necessary for supporting viral replication inside host cells; whereas, late genes are required for host cell lysis, viral assembly, and virion release. Recombinant adenoviruses that are generated in the laboratory as vectors can be either replication-deficient or replication-competent. Because the E1 gene is essential for viral replication, experimental depletion of the E1 gene generates adenoviruses that are capable of infecting the host cells but cannot grow in numbers because of defective replication.” [10]
“a specific producer cell line is required to provide trans-complementation to overcome the modification and allow viral production. This can occur in two ways; use of a producer cell line that contains specific adenoviral sequences incorporated into the cell genome to trans-complement, or use of a producer cell line that naturally complements for the modified Ad vector genome. This review concentrates on producer cell lines that complement non-replicating adenoviral vectors, starting with the historical HEK293 cell line developed in 1977 for first generation Ad vectors.” [11]
What prevents body stem cells acting like HEK293 and replicating the vector like a virus?
“As the lack of E1 renders recombinant adenoviral vectors replication-deficient, vector amplification and propagation must be done within cell lines which can provide E1 in trans. The HEK 293 cell line, a modified human embryonic kidney cell line, constitutively expresses E1 from AdHu5 has been the staple workhorse in the generation of recombinant adenoviral vectors for both preclinical and clinical applications… propagation of E1-deficient adenoviral vectors on the 293 cell line can lead to a small degree of contamination with replication-competent adenovirus, which may be one of the questions to address when preparing such vaccines for human applications… risk of replication-competent adenovirus formation” [12]
What prevents this risk? How was it controlled in each manufacturer? How was it controlled by the Governments? Is lack of answer the answer?
Consider the terrible context before answering: http://bit.ly/research2000
[1] Brodin P, Arditi M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens.13 May 2022 The Lancet. Gastroenterology & hepatology: Correspondence - Online First https://doi.org/10.1016/S2468-1253(22)00166-2
[2] Hierholzer JC. Adenoviruses in the immunocompromised host. Clin Microbiol Rev 1992;5:262–74. https://doi.org/10.1128/CMR.5.3.262
[3] Munoz FM, Piedra PA, Demmler GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis 1998;27:1194–200. https://doi.org/10.1086/514978
[4] Baker JM, Buchfellner M, Britt W, et al. Acute Hepatitis and Adenovirus Infection Among Children — Alabama, October 2021–February 2022. MMWR Morb Mortal Wkly Rep 2022;71:638–640. http://dx.doi.org/10.15585/mmwr.mm7118e1external icon.
[5] https://www.cdc.gov/flu/prevent/different-flu-vaccines.htm
[6] Gadour E, Hassan Z, Shrwani K. P31 Covid-19 induced hepatitis (CIH), definition and diagnostic criteria of a poorly understood new clinical syndrome. Gut 2020;69:A22. http://dx.doi.org/10.1136/gutjnl-2020-BASL.41
Wander, P., Epstein, M., & Bernstein, D. (2020). COVID-19 Presenting as Acute Hepatitis. The American journal of gastroenterology, 15 Apr 2020. 115(6), 941–942. https://doi.org/10.14309/ajg.0000000000000660
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/liver-disease.html
[7] Antala, S., Diamond, T., Kociolek, L. K., Shah, A. A., & Chapin, C. A. (2022). Severe Hepatitis in Pediatric COVID-19. 10 Feb 2022 Journal of pediatric gastroenterology and nutrition, Advance online publication. https://doi.org/10.1097/MPG.0000000000003404
[8] Garrido, I., Lopes, S., Simões, M. S., Liberal, R., Lopes, J., Carneiro, F., & Macedo, G. (2021). Autoimmune hepatitis after COVID-19 vaccine - more than a coincidence. 26 Oct 2021 Journal of autoimmunity, 125, 102741. https://doi.org/10.1016/j.jaut.2021.102741
Rela, M., Jothimani, D., Vij, M., Rajakumar, A., & Rammohan, A. (2021). Auto-immune hepatitis following COVID vaccination. 3 Jul 2021 Journal of autoimmunity, 123, 102688. https://doi.org/10.1016/j.jaut.2021.102688
[9] Technical Briefing: Investigation into acute hepatitis of unknown aetiology in children in England
https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON376
[10] https://www.news-medical.net/health/What-are-Adenovirus-Based-Vaccines.aspx based on:
Tatsis N. 2004. Adenoviruses as vaccine vectors. Molecular Therapy. https://www.sciencedirect.com/science/article/pii/S1525001604013425
Afkhami S. 2016. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Methods and Clinical Development. https://www.sciencedirect.com/science/article/pii/S2329050116301735
Zhang C. 2016. Adenoviral vector-based strategies against infectious disease and cancer. Human Vaccines and Immunotherapeutics. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994731/
[11] Kovesdi I, Hedley SJ. Adenoviral Producer Cells. Viruses. 2010; 2(8):1681-1703. https://doi.org/10.3390/v2081681
Mendonça, S.A., Lorincz, R., Boucher, P. et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. 5 Aug 2021 npj Vaccines 6, 97 (2021). https://doi.org/10.1038/s41541-021-00356-x
[12] Afkhami, S., Yao, Y., & Xing, Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. 2016 Molecular therapy. Methods & clinical development, 3, 16030. https://doi.org/10.1038/mtm.2016.30